<div id="readability-page-1"><p><span>Veeva Systems (NYSE:VEEV - Get Free Report)</span> had its target price hoisted by analysts at UBS Group from $185.00 to $215.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a &#34;neutral&#34; rating on the technology company's stock. UBS Group's price objective would suggest a potential upside of 7.47% from the stock's current price.</p><div><p><span></span><span>Get <strong>Veeva Systems</strong> alerts:</span></p></div><ul><li>Veeva Systems: Increasing NDR and Other Wins</li></ul><p>A number of other equities analysts also recently issued reports on the company. Citigroup cut their price objective on Veeva Systems from $274.00 to $256.00 and set a &#34;buy&#34; rating for the company in a report on Monday, June 3rd. Guggenheim raised their target price on Veeva Systems from $211.00 to $233.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, July 18th. Royal Bank of Canada reaffirmed an &#34;outperform&#34; rating and set a $250.00 price target on shares of Veeva Systems in a research report on Friday, June 21st. Truist Financial dropped their price objective on shares of Veeva Systems from $203.00 to $197.00 and set a &#34;hold&#34; rating on the stock in a report on Friday, June 14th. Finally, Stifel Nicolaus cut their target price on shares of Veeva Systems from $250.00 to $210.00 and set a &#34;buy&#34; rating for the company in a research report on Friday, May 31st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $229.64.</p><p><b>Read Our Latest Report on VEEV</b></p><h2>Veeva Systems Stock Up 0.4 %</h2><ul><li>Veeva Systems <span>NYSE: VEEV<span></span></span> Stock a Buy: Cloud Software for Life Sciences</li></ul><p>Shares of NYSE VEEV traded up $0.81 during midday trading on Monday, hitting $200.06. The stock had a trading volume of 87,684 shares, compared to its average volume of 951,015. The company has a market cap of $32.34 billion, a P/E ratio of 59.01, a PEG ratio of 1.93 and a beta of 0.80. The business's 50 day moving average is $186.60 and its 200-day moving average is $202.28. Veeva Systems has a 52 week low of $162.72 and a 52 week high of $236.90. </p><p>Veeva Systems (NYSE:VEEV - Get Free Report) last posted its quarterly earnings results on Thursday, May 30th. The technology company reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.10. Veeva Systems had a return on equity of 12.74% and a net margin of 22.34%. The firm had revenue of $650.35 million during the quarter, compared to analysts' expectations of $641.73 million. As a group, analysts expect that Veeva Systems will post 4.19 EPS for the current fiscal year. </p><h2>Insiders Place Their Bets</h2><p>In related news, SVP Jonathan Faddis sold 2,353 shares of the firm's stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $200.00, for a total value of $470,600.00. Following the transaction, the senior vice president now directly owns 9,035 shares of the company's stock, valued at approximately $1,807,000. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. In other Veeva Systems news, CFO Timothy S. Cabral sold 15,000 shares of the stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $184.33, for a total transaction of $2,764,950.00. Following the completion of the transaction, the chief financial officer now owns 8,391 shares of the company's stock, valued at $1,546,713.03. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Jonathan Faddis sold 2,353 shares of the business's stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $200.00, for a total value of $470,600.00. Following the completion of the sale, the senior vice president now directly owns 9,035 shares in the company, valued at approximately $1,807,000. The disclosure for this sale can be found here. 10.50% of the stock is currently owned by company insiders. </p><h2>Institutional Investors Weigh In On Veeva Systems</h2><p>Several large investors have recently added to or reduced their stakes in the business. Linscomb &amp; Williams Inc. purchased a new stake in shares of Veeva Systems during the fourth quarter worth $1,479,000. Robeco Institutional Asset Management B.V. grew its position in shares of Veeva Systems by 32.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 206,220 shares of the technology company's stock worth $365,000 after buying an additional 50,868 shares in the last quarter. APG Asset Management US Inc. purchased a new stake in shares of Veeva Systems during the fourth quarter worth approximately $5,756,000. Quantum Capital Management LLC NJ raised its holdings in Veeva Systems by 9.8% in the fourth quarter. Quantum Capital Management LLC NJ now owns 329,867 shares of the technology company's stock valued at $63,506,000 after acquiring an additional 29,525 shares in the last quarter. Finally, Eisler Capital UK Ltd. purchased a new position in Veeva Systems in the fourth quarter worth approximately $1,408,000. 88.20% of the stock is owned by hedge funds and other institutional investors. </p><h2>Veeva Systems Company Profile</h2> (Get Free Report)<p>Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.</p><h2>See Also</h2><ul><li>Five stocks we like better than Veeva Systems</li><li>Health Care Stocks Explained: Why You Might Want to Invest</li><li>Eli Lilly’s Path to the Next Trillion Market Capitalization </li><li>Most active stocks: Dollar volume vs share volume</li><li>Mobileye Global: CEO Makes $10 Million Bet on Future Strength</li><li>What Are Dividend Champions? How to Invest in the Champions</li><li>3 Stocks Increasing Dividend Payouts Ahead of Interest Rate Cuts</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVZFRVY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVZFRVY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ $5k to $1.3m in just 3 trades <span><span>(From Insiders Exposed)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTM0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTM0"/></p><h2>Should you invest $1,000 in Veeva Systems right now?</h2><p>Before you consider Veeva Systems, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veeva Systems wasn't on the list.</p><p>While Veeva Systems currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

VEEV

<p>UBS Group raised its price target for Veeva Systems (NYSE: VEEV) from $X.00 to $Y.00, maintaining a "neutral" rating. This adjusted target implies a potential upside of 7.47% from the current price. Various analysts have provided mixed ratings on Veeva, with a consensus of 1 sell, 6 holds, and 16 buy ratings, reflecting a "Moderate Buy" stance. Additionally, Veeva's recent stock performance shows a slight increase of 0.4%.</p>

Veeva Systems (NYSE:VEEV) PT Raised to $215.00